Pay in 4 interest-free payments of $27.23 Learn more
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4
is a next-generation proteasome inhibitor with demonstrated preclinical and clinical antimyeloma activity
MCT-14-0775
InChiKey: IIJDFXNUWZTHIM-NRFANRHFSA-N
InChiKey: LAZPBGZRMVRFKY-HNCPQSOCSA-N
26S)-3-[(1R)-2-carbamoyl-1-hydroxyethyl]-11
Emricasan Catalog No.:M10978-10 is a next-generation proteasome inhibitorEmricasan, also known as IDN 6556 and PF 03491390, is a first in class caspase inhibitor in clinical trials for the treatment of liver diseases. Emricasan (IDN 6556) decreases liver injury and fibrosis in a murine model of non alcoholic steatohepatitis. IDN6556 facilitates marginal mass islet engraftment in a porcine islet autotransplant model. Oral IDN 6556 may lower aminotransferase activity in patients with chronic hepatitis C. Orally administered
US$ 589.58
US$ 1726.82